ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,132.21
1.34%
Dow Jones
38,679.36
1.19%
US Dollar vs MXN
16.96255
-0.06%
Brent Oil
82.77
-1.03%
Bitcoin
61,749.10
4.44%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Eterna Therapeutics Inc (ERNA)

  7. Eterna Therapeutics Inc (ERNA) Noticias

ERNA Eterna Therapeutics Inc

1.72
0.01 (0.58%)
Última actualización: 13:23:58
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Eterna Therapeutics Inc ERNA NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.01 0.58% 1.72 13:23:58
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
1.80 1.72 2.00 1.71
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
20/2/202407:30GLOBEEterna Therapeutics Announces the Appointment of Peter..
16/2/202416:30EDGAR2Form 3 - Initial statement of beneficial ownership of..
16/2/202406:30EDGAR2Form 8-K - Current report
31/1/202406:05EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
24/1/202415:15EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
22/1/202423:15EDGAR2Form EFFECT - Notice of Effectiveness
19/1/202415:16EDGAR2Form 8-K - Current report
19/1/202409:31EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
16/1/202415:16EDGAR2Form S-8 - Securities to be offered to employees in employee..
12/1/202415:49EDGAR2Form S-3 - Registration statement under Securities Act of..
03/1/202416:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202416:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202416:01EDGAR2Form 3 - Initial statement of beneficial ownership of..
03/1/202415:15GLOBEEterna Therapeutics Grants New President and CEO Sanjeev..
22/12/202311:05EDGAR2Form SC 13D/A - General statement of acquisition of..
20/12/202315:20EDGAR2Form 8-K - Current report
20/12/202315:15GLOBEEterna Therapeutics Names Sanjeev Luther as President and..
20/12/202314:24EDGAR2Form SC 13G - Statement of acquisition of beneficial..
20/12/202309:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/12/202320:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/12/202317:56GLOBEEterna Therapeutics Announces $9.2 Million Convertible Debt..
14/12/202315:30EDGAR2Form 8-K - Current report
16/11/202315:16EDGAR2Form 8-K - Current report
13/11/202316:30EDGAR2Form 3 - Initial statement of beneficial ownership of..
13/11/202307:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
01/11/202307:34EDGAR2Form 8-K - Current report
01/11/202307:30GLOBEEterna Therapeutics Appoints James Bristol, Ph.D.,..
05/10/202315:30EDGAR2Form 8-K - Current report
26/9/202315:30EDGAR2Form 8-K/A - Current report: [Amend]
08/9/202305:07EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
07/9/202316:26EDGAR2Form SC 13D/A - General statement of acquisition of..
06/9/202307:00GLOBEEterna Therapeutics Announces Initiation of Development..
05/9/202307:30GLOBEEterna Therapeutics Appoints Biopharma Industry Veteran..
01/9/202316:00EDGAR2Form 3 - Initial statement of beneficial ownership of..
31/8/202315:15EDGAR2Form 8-K - Current report
28/8/202315:57EDGAR2Form SC 13G - Statement of acquisition of beneficial..
25/8/202318:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/8/202306:00EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
14/8/202315:59EDGAR2Form S-3 - Registration statement under Securities Act of..
11/8/202315:11EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/8/202316:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/8/202316:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/8/202315:10EDGAR2Form 8-K - Current report
02/8/202316:25EDGAR2Form 8-K - Current report
26/7/202316:05EDGAR2Form SC 13D/A - General statement of acquisition of..
18/7/202315:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/7/202315:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/7/202307:05EDGAR2Form 8-K - Current report
18/7/202307:00GLOBEEterna Therapeutics Announces Completion of $8.7 Million of..
18/7/202305:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..

Su Consulta Reciente

NASDAQ
ERNA
Eterna Therapeutics
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados